AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|
21.2 C
New York
Friday, October 16, 2026

Tag: cancer

newssourceFORcompanycontentinformation1releasesmarket

The 34th Annual Giant BBQ Battle Hits Washington D.C. This Weekend, Bigger, Bolder, and Tastier Than Ever

Tito Puente Jr., Rare Essence, E.U., and Reverend Peyton's Big Damn Band headline an all-star musical lineup alongside champion pitmasters and culinary stars, including...

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar’s Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

HOFSETH BIOCARE ASA: CONTEMPLATED PRIVATE PLACEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

Resultater fra Ultimovacs’ DOVACC fase II-studie bekrefter avslutningen av UV1-programmet, i tråd med tidligere kommunisert plan

Oslo, 26. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av solide kreftformer, kunngjør i dag at den NSGO-CTU sponsede fase II DOVACC kliniske studie (NCT04742075) som testet Ultimovacs' UV1 kreftvaksine ikke oppnådde sitt primære endepunkt om å forbedre progresjonsfri overlevelse (PFS). UV1 ble overtatt gjennom virksomhetssammenslåingen mellom de to selskapene i 2025. Dette avslutter den tidligere kommuniserte avviklingsfasen av UV1-kreftvaksine-programmet, og Zelluna anser nå programmet som avsluttet.

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at...

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges...

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Energy Fuels Announces Election of Directors

DENVER, June 25, 2026 /CNW/ - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based critical materials company focused on uranium, rare earth...

Energy Fuels Announces Election of Directors

DENVER, June 25, 2026 /PRNewswire/ - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based critical materials company focused on uranium, rare earth...

DecisionDx®-Melanoma’s i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity...

Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026

NEW YORK, 25 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des thérapies cellulaires et géniques, a tenu son assemblée générale mixte ce jour à 14h30, heure de Paris, à l’auditorium du site Biopark, situé au 11 rue Watt, 4ème étage, 75013 Paris, France.

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers